Pralsetinib pharmaceutical compositions

An immediate release oral dosage form comprising:

• a) an amorphous solid dispersion comprising:
• pralsetinib, or a pharmaceutically acceptable salt thereof, and hydroxypropyl methylcellulose E3, wherein the pralsetinib or an equivalent amount of pharmaceutically acceptable salt thereof and the hydroxypropyl methyl cellulose E3 are in about a 1:1 weight ratio;
• b) an effervescent couple comprising about 3 to about 13 w/w % citric acid and about 7 to about 30 w/w % sodium bicarbonate;
• wherein w/w % is based on the total weight of the oral dosage form;
• c) a diluent;
• and
• d) moisture scavenger and a lubricant,
• wherein the immediate release oral dosage form comprises the amorphous solid dispersion from about 25% to about 65% percent by weight of the immediate release oral dosage form, based on the total weight of the oral dosage form, and
• the immediate release oral dosage form is a tablet or a capsule.